Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA

BMJ Open 2024;14:e072300 doi: 10.1136/bmjopen-2023-072300

Unadjusted time to all-cause discontinuation was significantly longer with baricitinib treatment versus TNFi (estimated median prescription survival time of 704 days versus 448 days; log-rank P<0.01). This difference increased when only comparing differences for b/tsDMARD-naïve patients treated with baricitinib versus tofacitinib.

Gilbert, et al. used data from the Swiss Clinical Quality Management database from 1 September 2017–1 June 2020 to compare the time to all-cause discontinuation for baricitinib, TNFi and other modes of action.

Keywords:


Publication thumbnail: Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA
LinkedIn